Q2 2025 EPS Estimates for Novartis AG Raised by Zacks Research (NYSE:NVS)

Novartis AG (NYSE:NVS) – Investment analysts at Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for Novartis in a report issued on Monday, September 2nd. Zacks Research analyst E. Bagri now anticipates that the company will earn $2.07 per share for the quarter, up from their prior forecast of $2.06. The consensus estimate for Novartis’ current full-year earnings is $7.48 per share. Zacks Research also issued estimates for Novartis’ Q1 2026 earnings at $2.03 EPS.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating the consensus estimate of $1.87 by $0.10. The business had revenue of $12.87 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Novartis had a net margin of 33.76% and a return on equity of 34.56%. During the same period in the previous year, the business posted $1.83 EPS.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $121.00 price objective (up previously from $119.00) on shares of Novartis in a research note on Thursday. Jefferies Financial Group lowered Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a research note on Friday, July 19th. Finally, Barclays raised shares of Novartis to a “strong sell” rating in a report on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $118.38.

Novartis Trading Up 0.7 %

NYSE NVS opened at $119.37 on Thursday. Novartis has a 1 year low of $92.19 and a 1 year high of $120.92. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. The company has a market capitalization of $243.99 billion, a PE ratio of 16.11, a P/E/G ratio of 1.77 and a beta of 0.57. The company has a fifty day moving average of $112.25 and a 200 day moving average of $104.31.

Hedge Funds Weigh In On Novartis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James & Associates raised its position in shares of Novartis by 1.3% during the 2nd quarter. Raymond James & Associates now owns 536,607 shares of the company’s stock worth $57,127,000 after purchasing an additional 6,767 shares during the last quarter. Manning & Napier Advisors LLC purchased a new position in shares of Novartis in the second quarter valued at approximately $15,044,000. O Shaughnessy Asset Management LLC boosted its stake in shares of Novartis by 6.5% in the first quarter. O Shaughnessy Asset Management LLC now owns 180,764 shares of the company’s stock worth $17,485,000 after acquiring an additional 11,080 shares during the last quarter. TD Asset Management Inc increased its position in shares of Novartis by 314.8% during the fourth quarter. TD Asset Management Inc now owns 55,096 shares of the company’s stock worth $5,563,000 after purchasing an additional 41,815 shares in the last quarter. Finally, FORA Capital LLC acquired a new position in Novartis in the 1st quarter valued at $2,968,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.